Literature DB >> 16380547

Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.

Sekar Kathiresan1, James D Otvos, Lisa M Sullivan, Michelle J Keyes, Ernst J Schaefer, Peter W F Wilson, Ralph B D'Agostino, Ramachandran S Vasan, Sander J Robins.   

Abstract

BACKGROUND: Levels of LDL cholesterol (LDL-C) are frequently not elevated in individuals with the metabolic syndrome (MetSyn). However, the atherogenic potential of LDL may depend on the number and size of LDL particles in addition to the cholesterol content of LDL. METHODS AND
RESULTS: We examined the sex-specific cross-sectional relations of small LDL particle number (determined by nuclear magnetic resonance spectroscopy) to the presence of MetSyn and its components in 2993 Framingham Heart Study participants (mean age, 51 years; 53% women) without cardiovascular disease (CVD) and the relations of small LDL particle number to CVD incidence in people with MetSyn. The MetSyn (> or =3 of 5 traits as defined by the National Cholesterol Education Adult Treatment Panel III) was present in 27% of men and 17% of women. In both sexes, small LDL particle number increased from 0 to 5 MetSyn traits, a pattern partly accounted for by strong correlations between small LDL particle number and serum triglycerides (r=0.61, P<0.0001) and HDL-C (r=-0.55, P<0.0001). Compared with participants without the MetSyn, those with the MetSyn had a higher CVD event rate. However, among participants with the MetSyn, CVD rates were similar for groups with an elevated versus a lower number of small LDL particles (defined by the sex-specific median).
CONCLUSIONS: Small LDL particle number is elevated in the MetSyn, increases with the number of MetSyn components, and most prominently is correlated with triglycerides and HDL-C. Whereas increased small LDL particle number identified the MetSyn with high sensitivity, a higher small LDL particle number was not associated with greater CVD event rates in people with the MetSyn.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380547     DOI: 10.1161/CIRCULATIONAHA.105.567107

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  98 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

Review 2.  Is it LDL particle size or number that correlates with risk for cardiovascular disease?

Authors:  H Robert Superko; Radhika R Gadesam
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

3.  Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.

Authors:  Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-09       Impact factor: 3.478

Review 4.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

5.  The Associations of Indices of Obesity with Lipoprotein Subfractions in Japanese American, African American and Korean Men.

Authors:  Nobutaka Hirooka; Chol Shin; Kamal H Masaki; Daniel Edmundowicz; Jina Choo; Emma J M Barinas-Mitchell; Bradley J Willcox; Kim Sutton-Tyrrell; Aiman El-Saed; Iva Miljkovic-Gacic; Takayoshi Ohkubo; Katsuyuki Miura; Hirotsugu Ueshima; Lewis H Kuller; Akira Sekikawa
Journal:  Glob Heart       Date:  2013-09-01

Review 6.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

7.  Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

Authors:  K G Lagos; T D Filippatos; V Tsimihodimos; I F Gazi; C Rizos; A D Tselepis; D P Mikhailidis; Moses S Elisaf
Journal:  Lipids       Date:  2008-10-28       Impact factor: 1.880

8.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

9.  Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy.

Authors:  Monique A Ford; Joseph P McConnell; Shahar Lavi; Charanjit S Rihal; Abhiram Prasad; Gurpreet S Sandhu; Stacy J Hartman; Lilach O Lerman; Amir Lerman
Journal:  Atherosclerosis       Date:  2009-05-06       Impact factor: 5.162

10.  Serum small dense low-density lipoprotein concentrations are elevated in patients with significant coronary artery stenosis and are related to features of the metabolic syndrome.

Authors:  Shima Yazdandoust; Seyyed Mohammad Reza Parizadeh; Mohsen Moohebati; Parichehreh Yaghmaei; Amir Ali Rahsepar; Shima Tavallaie; Mohammad Soukhtanloo; Roshanak Khojasteh; Roghayeh Paydar; Afsoon Fazlinezhad; Homa Falsoleiman; Mashalla Dehghani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Lipids       Date:  2012-08-18       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.